Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal phase 3 study of paxalisib versus standard of care (SOC) in patients with newly diagnosed unmethylated glioblastoma

Next Previous
Trial Profile

A pivotal phase 3 study of paxalisib versus standard of care (SOC) in patients with newly diagnosed unmethylated glioblastoma

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 22 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paxalisib (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Registrational; Therapeutic Use

Most Recent Events

  • 22 May 2025 Planned number of patients changed to 366.
  • 22 May 2025 New trial record
  • 15 May 2025 According to Kazia Therapeutics media release, company is exploring various bids from Contract Research Organizations (CROs) in parallel to discussions with strategic partners and cooperative groups to participate or fully fund the trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top